Acurx Pharmaceuticals Sets Q2 2026 Earnings Call Amid Phase 3 Trial Preparations
Event summary
- Acurx Pharmaceuticals will discuss Q2 2026 financial results on August 14, 2026.
- CEO David P. Luci and CFO Robert G. Shawah to host the conference call at 8:00 AM ET.
- Company's lead antibiotic candidate ibezapolstat is Phase 3 ready for C. difficile infection treatment.
- Pilot trial for multiply-recurrent CDI (rCDI) expected to begin in Q4 2026.
The big picture
Acurx Pharmaceuticals is advancing its lead antibiotic candidate, ibezapolstat, through critical Phase 3 trials amid growing concerns over antibiotic resistance. The company's focus on developing Gram-positive selective spectrum antibiotics positions it to address urgent public health threats like C. difficile infections. Success in these trials could significantly expand Acurx's market opportunities and validate its innovative approach to bacterial infections.
What we're watching
- Regulatory Pathway
- Whether ibezapolstat's Phase 3 trials will meet FDA and EMA requirements for approval.
- Clinical Trial Progress
- The pace at which the rCDI pilot trial enrolls patients and informs future studies.
- Market Positioning
- How Acurx differentiates ibezapolstat in a competitive landscape for C. difficile treatments.
Related topics